Literature DB >> 20135751

Burden of childhood rotavirus disease on health systems in the United States.

T Christopher Mast1, Emmanuel B Walter, Monique Bulotsky, Shazia S Khawaja, Daniel J DiStefano, Mary K Sandquist, Walter L Straus, Mary Allen Staat.   

Abstract

BACKGROUND: To determine the burden of rotavirus disease before the introduction of rotavirus vaccines.
METHODS: From February 2005 to June 2006, prospective rotavirus surveillance was conducted in Cincinnati, Ohio, and Durham, North Carolina. Children < 5 years of age presenting at hospitals and outpatient clinics with acute gastroenteritis (AGE) of < 72 hours duration were enrolled. Stool samples were first tested for rotavirus by EIA and the VP7 type was determined by RT-polymerase chain reaction for rotavirus-positive samples. Medical costs were obtained from billing or accounting data.
RESULTS: A total of 1998 children were enrolled, with a mean age of 16.9 months. Among 1601 (80%) patients with a stool specimen, 44% were rotavirus positive. The rotavirus detection rate was 38% for patients admitted to hospital, 60% for patients requiring a short-stay hospital visit (< 24 hour hospitalization), 49% for emergency department visits, and 37% for outpatient visits. During the rotavirus season, rotavirus accounted for 56% of all AGE cases. Only 11% of rotavirus-positive children were assigned the rotavirus-specific ICD-9-CM code and this proportion varied considerably by clinical setting. The VP7 genotypes identified were G1, 79%; G2, 14%; G3, 5%; G9, 1%; and G12, 1%. For children hospitalized with rotavirus, the estimated median direct cost was $4565, the average length of stay was 1.9 days, and parents lost 3.4 days of work. For short-stay, emergency department, and outpatient visits, the estimated median costs were $3160, $867, and $75, respectively.
CONCLUSIONS: Before the widespread use of rotavirus vaccines in the United States, rotavirus was prevalent among children treated in hospital-based and outpatient settings and was associated with a substantial proportion of pediatric medical visits for AGE.

Entities:  

Mesh:

Year:  2010        PMID: 20135751     DOI: 10.1097/inf.0b013e3181ca7e2e

Source DB:  PubMed          Journal:  Pediatr Infect Dis J        ISSN: 0891-3668            Impact factor:   2.129


  17 in total

1.  Decline in rotavirus hospitalizations following the first three years of vaccination in Castile-La Mancha, Spain.

Authors:  Olga Redondo; Rosa Cano; Lorena Simón
Journal:  Hum Vaccin Immunother       Date:  2015       Impact factor: 3.452

2.  Potential impact of accelerating the primary dose of rotavirus vaccine in infants.

Authors:  Elizabeth E Halvorson; Timothy R Peters; Beverly M Snively; Katherine A Poehling
Journal:  Vaccine       Date:  2012-02-26       Impact factor: 3.641

Review 3.  Rotavirus infections and vaccines: burden of illness and potential impact of vaccination.

Authors:  Keith Grimwood; Stephen B Lambert; Richard J Milne
Journal:  Paediatr Drugs       Date:  2010-08-01       Impact factor: 3.022

4.  Using molecular epidemiology to trace transmission of nosocomial norovirus infection.

Authors:  Faizel H A Sukhrie; Matthias F C Beersma; Albert Wong; Bas van der Veer; Harry Vennema; Jolanda Bogerman; Marion Koopmans
Journal:  J Clin Microbiol       Date:  2010-12-15       Impact factor: 5.948

5.  A significant and consistent reduction in rotavirus gastroenteritis hospitalization of children under 5 years of age, following the introduction of universal rotavirus immunization in Israel.

Authors:  Khitam Muhsen; Uri Rubenstein; Eias Kassem; Sophy Goren; Yaakov Schachter; Adi Kremer; Lester M Shulman; Moshe Ephros; Dani Cohen
Journal:  Hum Vaccin Immunother       Date:  2015       Impact factor: 3.452

6.  Laboratory-Confirmed Rotavirus Disease in Utah Children: Clinical and Economic Impact of Rotavirus Vaccination.

Authors:  Angel Herrera Guerra; Chris Stockmann; Andrew T Pavia; Adam L Hersh; Emily A Thorell; Hsin Yi Weng; Kent Korgenski; Carrie L Byington; Krow Ampofo
Journal:  J Pediatric Infect Dis Soc       Date:  2012-06-22       Impact factor: 3.164

7.  Cost effectiveness of infant vaccination for rotavirus in Canada.

Authors:  Doug Coyle; Kathryn Coyle; Julie A Bettinger; Scott A Halperin; Wendy Vaudry; David W Scheifele; Nicole Le Saux
Journal:  Can J Infect Dis Med Microbiol       Date:  2012       Impact factor: 2.471

8.  Rotavirus-associated hospitalization and emergency department costs and rotavirus vaccine program impact.

Authors:  April Kilgore; Stephanie Donauer; Kathryn M Edwards; Geoffrey A Weinberg; Daniel C Payne; Peter G Szilagyi; Marilyn Rice; Amy Cassedy; Ismael R Ortega-Sanchez; Umesh D Parashar; Mary Allen Staat
Journal:  Vaccine       Date:  2013-07-08       Impact factor: 3.641

9.  Norovirus and medically attended gastroenteritis in U.S. children.

Authors:  Daniel C Payne; Jan Vinjé; Peter G Szilagyi; Kathryn M Edwards; Mary Allen Staat; Geoffrey A Weinberg; Caroline B Hall; James Chappell; David I Bernstein; Aaron T Curns; Mary Wikswo; S Hannah Shirley; Aron J Hall; Benjamin Lopman; Umesh D Parashar
Journal:  N Engl J Med       Date:  2013-03-21       Impact factor: 91.245

10.  Global seasonality of rotavirus disease.

Authors:  Manish M Patel; Virginia E Pitzer; Wladimir J Alonso; David Vera; Ben Lopman; Jacqueline Tate; Cecile Viboud; Umesh D Parashar
Journal:  Pediatr Infect Dis J       Date:  2013-04       Impact factor: 2.129

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.